Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Haas

Showing results (471-480 of 542) with videos related to

Pageof 55
Sort By:
Medrxiv : the Preprint Server for Health Sciences|September 11, 2023
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohortGustavo Amorim, James Jaworski, Marcelo Cordeiro-Santos, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2006
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyHeather J Ribaudo, David W Haas, Camlin Tierney, et al.
Pharmacogenetics and Genomics|May 31, 2018
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse eventsDavid W Haas, Yuki Bradford, Anurag Verma, et al.
Pharmacogenetics and Genomics|October 20, 2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEmily R Holzinger, Benjamin Grady, Marylyn D Ritchie, et al.
Environmental Microbiology|May 17, 2021
The quorum-sensing systems of Vibrio campbellii DS40M4 and BB120 are genetically and functionally distinctChelsea A Simpson, Blake D Petersen, Nicholas W Haas, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in BrazilJacqueline A Piekos, Gustavo Amorim, Felipe Ridolfi, et al.
Pharmacogenetics and Genomics|February 28, 2020
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptivesDavid W Haas, Yoninah S Cramer, Catherine Godfrey, et al.
Pharmacogenetics and Genomics|August 9, 2021
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosisDavid W Haas, Rosie Mngqibisa, Jose Francis, et al.
British Journal of Clinical Pharmacology|February 9, 2024
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South AfricaRephaim Mpofu, Aida N Kawuma, Roeland E Wasmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2021
A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment OutcomesLauren S Peetluk, Peter F Rebeiro, Felipe M Ridolfi, et al.
Pageof 55

Showing results (471-480 of 542) with videos related to

Sort By:
Pageof 55
Medrxiv : the Preprint Server for Health Sciences|September 11, 2023
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohortGustavo Amorim, James Jaworski, Marcelo Cordeiro-Santos, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2006
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyHeather J Ribaudo, David W Haas, Camlin Tierney, et al.
Pharmacogenetics and Genomics|May 31, 2018
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse eventsDavid W Haas, Yuki Bradford, Anurag Verma, et al.
Pharmacogenetics and Genomics|October 20, 2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEmily R Holzinger, Benjamin Grady, Marylyn D Ritchie, et al.
Environmental Microbiology|May 17, 2021
The quorum-sensing systems of Vibrio campbellii DS40M4 and BB120 are genetically and functionally distinctChelsea A Simpson, Blake D Petersen, Nicholas W Haas, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in BrazilJacqueline A Piekos, Gustavo Amorim, Felipe Ridolfi, et al.
Pharmacogenetics and Genomics|February 28, 2020
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptivesDavid W Haas, Yoninah S Cramer, Catherine Godfrey, et al.
Pharmacogenetics and Genomics|August 9, 2021
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosisDavid W Haas, Rosie Mngqibisa, Jose Francis, et al.
British Journal of Clinical Pharmacology|February 9, 2024
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South AfricaRephaim Mpofu, Aida N Kawuma, Roeland E Wasmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2021
A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment OutcomesLauren S Peetluk, Peter F Rebeiro, Felipe M Ridolfi, et al.
Pageof 55